Literature DB >> 16183026

Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities.

Maria Clara Zaccaro1, Hong Boon Lee, Mookda Pattarawarapan, Zebin Xia, Antoine Caron, Pierrre-Jean L'Heureux, Yoshua Bengio, Kevin Burgess, H Uri Saragovi.   

Abstract

We designed a minilibrary of 55 small molecule peptidomimetics based on beta-turns of the neurotrophin growth factor polypeptides neurotrophin-3 (NT-3) and nerve growth factor (NGF). Direct binding, binding competition, and biological screens identified agonistic ligands of the ectodomain of the neurotrophin receptors TrkC and TrkA. Agonism is intrinsic to the peptidomimetic ligand (in the absence of neurotrophins), and/or can also be detected as potentiation of neurotrophin action. Remarkably, some peptidomimetics afford both neurotrophic activities of cell survival and neuronal differentiation, while others afford discrete signals leading to either survival or differentiation. The high rate of hits identified suggests that focused minilibraries may be desirable for developing bioactive ligands of cell surface receptors. Small, selective, proteolytically stable ligands with defined biological activity may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183026     DOI: 10.1016/j.chembiol.2005.06.015

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  16 in total

1.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

2.  Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.

Authors:  Jing Liu; Fouad Brahimi; H Uri Saragovi; Kevin Burgess
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

3.  Identification of a molecular activator for insulin receptor with potent anti-diabetic effects.

Authors:  Kunyan He; Chi-Bun Chan; Xia Liu; Yonghui Jia; Hongbo R Luo; Stefan A France; Yang Liu; W David Wilson; Keqiang Ye
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

4.  A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist.

Authors:  Fouad Brahimi; Jing Liu; Andrey Malakhov; Shafinaz Chowdhury; Enrico O Purisima; Ljubica Ivanisevic; Antoine Caron; Kevin Burgess; H Uri Saragovi
Journal:  Biochim Biophys Acta       Date:  2010-06-19

5.  One-pot high-throughput synthesis of beta-turn cyclic peptidomimetics via "volatilizable" supports.

Authors:  Yangmei Li; Yongping Yu; Marc Giulianotti; Richard A Houghten
Journal:  J Org Chem       Date:  2009-03-06       Impact factor: 4.354

Review 6.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

7.  A peptidomimetic of NT-3 acts as a TrkC antagonist.

Authors:  Fouad Brahimi; Andrey Malakhov; Hong Boon Lee; Mookda Pattarawarapan; Lubijca Ivanisevic; Kevin Burgess; H Uri Saragovi
Journal:  Peptides       Date:  2009-07-30       Impact factor: 3.750

8.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

Review 9.  Ligand bias in receptor tyrosine kinase signaling.

Authors:  Kelly Karl; Michael D Paul; Elena B Pasquale; Kalina Hristova
Journal:  J Biol Chem       Date:  2020-10-29       Impact factor: 5.157

Review 10.  Small molecule activators of the Trk receptors for neuroprotection.

Authors:  Nicholas J G Webster; Michael C Pirrung
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.